格隆汇12月15日丨昂利康(002940.SZ)公布，公司子公司浙江昂利康医药销售有限公司于2025年12月12 日以现金方式收到一笔与收益相关的政府补助资金1047.1万元，占公司最近一期经审计的归属于上市公 司股东净利润的13.03%。 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-102 浙江昂利康制药股份有限公司（以下简称"昂利康"或"公司"）子公司浙 江昂利康医药销售有限公司（以下简称"昂利康医药销售"）于 2025 年 12 月 12 日以现金方式收到一笔与收益相关的政府补助资金 1,047.1 万元，占公司最近 一期经审计的归属于上市公司股东净利润的 13.03%。现将具体情况公告如下： 一、获取补助的基本情况 单位：人民币元 | 获得补助 | 补助金额 | 收到补助时间 | | | 补助类型 | 是否与公司日常 | 是否具有 | | --- | --- | --- | --- | --- | --- | --- | --- | | 的主体 | | | | | | 经营活动相关 | 可持续性 | | 昂利康医 | 10,471,000 | 2025 年 月 12 | 12 | 日 | 与收益相 | 是 | 否 | | 药销售 | | | | | 关 | | | 二、补助的类型及对上市公司的影响 1、补助的类型 浙江昂利康制药股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整 ...

Core Viewpoint - Recently, the company announced that it has received the drug registration certificate for Diclofenac Sodium Enteric-coated Tablets and the approval notice for the supplemental application of Sacubitril/Valsartan Tablets from the National Medical Products Administration [2] Group 1 - The company has been granted a drug registration certificate for Diclofenac Sodium Enteric-coated Tablets [2] - The company has also received an approval notice for the supplemental application of Sacubitril/Valsartan Tablets [2]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

Core Viewpoint - Company received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for the supplemental application of Sacubitril/Valsartan Tablets from the National Medical Products Administration [1] Group 1: Product Approvals - Diclofenac Sodium Enteric-Coated Tablets are indicated for inflammatory and degenerative rheumatic diseases, various non-articular soft tissue rheumatic pain, acute gout attacks, acute mild to moderate pain, and as an adjunct treatment for severe pain infections in the ear, nose, and throat [1] - Sacubitril/Valsartan Tablets are indicated for the treatment of chronic heart failure in adults with reduced ejection fraction and for primary hypertension [1] Group 2: Collaboration and Market Launch - The Sacubitril/Valsartan Tablets were developed in collaboration with Suzhou Pengxu Pharmaceutical Technology Co., Ltd. and Suzhou Jingyun Pharmaceutical Technology Co., Ltd. [1] - The 200mg formulation of Sacubitril/Valsartan Tablets is set to be approved for market launch in June 2024, and the company has received approval for an additional 100mg specification [1]

Core Viewpoint - The company announced the receipt of drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets, indicating a positive development in its product pipeline [1] Group 1: Product Approvals - The National Medical Products Administration issued a drug registration certificate for Diclofenac Sodium Enteric-Coated Tablets, with a specification of 25mg and a validity period until December 8, 2030, which is considered equivalent to passing the consistency evaluation [1] - The company received approval for an additional specification of 100mg for Sacubitril/Valsartan Sodium Tablets, with the approval valid until June 27, 2029 [1] Group 2: Market Impact - The new approvals will enhance the company's product lineup and specifications, but the sales of these drugs may be influenced by policy and market factors, leading to uncertainties [1]

Core Insights - The company Anglikon (002940) has received regulatory approvals for two pharmaceutical products, enhancing its product pipeline and specifications [1] Group 1 - The company announced the receipt of a drug registration certificate for Diclofenac Sodium Enteric-Coated Tablets [1] - The company also received a supplemental approval notice for Sacubitril/Valsartan Sodium Tablets in the 100mg specification [1] - These approvals are expected to further enrich the company's product offerings [1]

证券代码：002940 证券简称：昂利康 公告编号：2025-101 | 药品通用名称 | 双氯芬酸钠肠溶片 | | | --- | --- | --- | | 主要成份 | 双氯芬酸钠 | | | 剂型 | 片剂 | | | 申请事项 | 药品注册（境内生产） | | | 注册分类 | 化学药品 类 4 | | | 规格 | 25mg | | | 受理号 | CYHS2402146 | | | 药品批准文号 | 国药准字 H20256225 | | | 药品批准文号有效期 | 至 2030 12 月 08 日 | 年 | | 上市许可持有人 | 名称：浙江昂利康制药股份有限公司 | | | | 地址：浙江省嵊州市嵊州大道北 号 1000 | | | 生产企业 | 名称：浙江昂利康制药股份有限公司 | | | | 地址：绍兴市嵊州市嵊州大道北 号 1000 | | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经 审查，本品符合药品注册的有关要求，批准注册，发 | | | | 给药品注册证书。 | | （一）药品注册证书主要内容 （二）药品补充申请批准通知书 1 | 药品通用名称 | 沙库巴曲 ...

Core Insights - The core viewpoint of the articles highlights that Anglikang has been recognized for its strong commitment to research and development (R&D) by being included in the "Top 200 R&D Investment" and "Top 200 Invention Patents" lists in Zhejiang Province, reflecting its comprehensive strength in innovation [1][2]. Group 1: Company Overview - Anglikang primarily engages in the production and manufacturing of pharmaceuticals, including chemical raw materials, chemical formulations, pharmaceutical excipients, and specialty intermediates [1]. - The company’s product range covers various therapeutic areas such as anti-infectives, cardiovascular, urology (kidney diseases), anesthetics, and anti-androgens [1][3]. Group 2: R&D and Innovation Strategy - As a modern enterprise focused on the pharmaceutical health sector, Anglikang prioritizes R&D innovation as its core development strategy, establishing a comprehensive R&D system that meets international standards [2]. - The company has significantly increased its R&D investment, forming specialized teams to address clinical needs and focusing on optimizing specialty generics and developing improved new drugs [2]. Group 3: Patent and Technology Development - Anglikang has accumulated over a hundred invention patents, particularly in cardiovascular, kidney disease, and anesthetic pain relief areas, showcasing its strength in patent innovation and technology transfer [2]. - The company has established a robust mechanism for converting patent technologies into clinically valuable and market-recognized pharmaceuticals, effectively combining technological innovation with industrial development [2]. Group 4: Competitive Positioning - In a highly competitive domestic pharmaceutical market, Anglikang maintains a focus on R&D as its core driving force, emphasizing collaboration within the industry to develop high-quality products with clinical value [3]. - The company holds significant advantages in various segments, including oral cephalosporin raw materials, alpha-keto acid raw materials, cardiovascular formulations, inhalation anesthetics, and plant-derived cholesterol products [3]. Group 5: Future Outlook - The recognition from the two lists serves as an affirmation of Anglikang's innovation efforts and will motivate the company to continue advancing [3]. - Anglikang plans to maintain its R&D investments, enhance its patent portfolio, and promote the launch of more high-quality pharmaceutical products, contributing to the high-quality development of the private economy in Zhejiang Province and supporting public health initiatives [3].

智通财经APP讯，昂利康(002940.SZ)公告，公司收到国家药品监督管理局签发的恩格列净二甲双胍缓释 片(II)《药品注册证书》。恩格列净二甲双胍缓释片(II)是恩格列净和盐酸二甲双胍的复方制剂，适用于 正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者，用于改善这些患者的血糖控制。 ...